CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade Alimera Sciences, Inc. - ALIM CFD

2.41
3.21%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.24
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 2.49
Open* 2.51
1-Year Change* -55.81%
Day's Range* 2.38 - 2.51
52 wk Range 1.30-7.92
Average Volume (10 days) 107.41K
Average Volume (3 months) 13.10M
Market Cap 19.10M
P/E Ratio -100.00K
Shares Outstanding 7.40M
Revenue 55.78M
EPS -2.44
Dividend (Yield %) N/A
Beta 1.39
Next Earnings Date Jul 25, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 9, 2023 2.41 -0.03 -1.23% 2.44 2.52 2.35
Jun 8, 2023 2.49 -0.15 -5.68% 2.64 2.65 2.41
Jun 7, 2023 2.62 -0.05 -1.87% 2.67 2.71 2.57
Jun 6, 2023 2.75 0.10 3.77% 2.65 2.89 2.64
Jun 5, 2023 2.71 0.18 7.11% 2.53 2.80 2.53
Jun 2, 2023 2.57 0.06 2.39% 2.51 2.66 2.50
Jun 1, 2023 2.52 -0.08 -3.08% 2.60 2.60 2.51
May 31, 2023 2.67 0.19 7.66% 2.48 2.67 2.48
May 30, 2023 2.52 0.05 2.02% 2.47 2.55 2.47
May 26, 2023 2.49 0.08 3.32% 2.41 2.52 2.35
May 25, 2023 2.48 -0.02 -0.80% 2.50 2.51 2.37
May 24, 2023 2.41 0.23 10.55% 2.18 2.42 2.14
May 23, 2023 2.32 -0.19 -7.57% 2.51 2.55 2.21
May 22, 2023 2.45 0.28 12.90% 2.17 2.72 2.15
May 19, 2023 2.23 0.12 5.69% 2.11 2.30 2.02
May 18, 2023 2.34 -0.26 -10.00% 2.60 3.05 2.26
May 17, 2023 1.93 0.11 6.04% 1.82 1.94 1.78
May 16, 2023 1.79 0.21 13.29% 1.58 1.92 1.58
May 15, 2023 1.57 -0.03 -1.88% 1.60 1.68 1.56
May 12, 2023 1.56 -0.05 -3.11% 1.61 1.64 1.55

Alimera Sciences, Inc. Events

Time (UTC) Country Event
Wednesday, July 12, 2023

Time (UTC)

13:30

Country

US

Event

Alimera Sciences Inc Annual Shareholders Meeting
Alimera Sciences Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Tuesday, July 25, 2023

Time (UTC)

12:30

Country

US

Event

Q2 2023 Alimera Sciences Inc Earnings Release
Q2 2023 Alimera Sciences Inc Earnings Release

Forecast

-

Previous

-
Monday, November 13, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Alimera Sciences Inc Earnings Release
Q3 2023 Alimera Sciences Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 54.129 59.029 50.82 53.943 46.599
Revenue 54.129 59.029 50.82 53.943 46.599
Cost of Revenue, Total 7.977 7.03 6.941 6.626 4.308
Gross Profit 46.152 51.999 43.879 47.317 42.291
Total Operating Expense 65.769 57.438 51.321 59.217 58.035
Selling/General/Admin. Expenses, Total 38.858 35.843 32.036 38.958 38.042
Research & Development 16.228 13.778 9.668 10.992 11.274
Depreciation / Amortization 2.706 2.579 2.676 2.641 2.645
Unusual Expense (Income) 0 -1.792 0 1.766
Operating Income -11.64 1.591 -0.501 -5.274 -11.436
Interest Income (Expense), Net Non-Operating -5.789 -4.997 -4.906 -4.953 -4.84
Net Income Before Taxes -18.079 -3.934 -5.407 -10.227 -16.276
Net Income After Taxes -18.107 -4.372 -5.339 -10.443 -16.382
Net Income Before Extra. Items -18.107 -4.372 -5.339 -10.443 -16.382
Net Income -18.107 -4.372 -5.339 -10.443 -16.382
Income Available to Common Excl. Extra. Items -18.107 -4.372 -5.339 -10.443 21.948
Income Available to Common Incl. Extra. Items -18.107 -4.372 -5.339 -10.443 21.948
Diluted Net Income -18.107 -4.372 -5.339 -10.443 21.948
Diluted Weighted Average Shares 6.99685 6.59524 5.11766 4.7702 5.91587
Diluted EPS Excluding Extraordinary Items -2.58788 -0.6629 -1.04325 -2.18921 3.71002
Diluted Normalized EPS -2.58788 -0.83951 -1.04325 -2.18921 3.90406
Other Operating Expenses, Total
Total Extraordinary Items 0 0
Total Adjustments to Net Income 0 38.33
Other, Net -0.65 -0.528
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 13.546 14.029 13.598 14.604 11.898
Revenue 13.546 14.029 13.598 14.604 11.898
Cost of Revenue, Total 2.028 2.125 2.006 2.166 1.68
Gross Profit 11.518 11.904 11.592 12.438 10.218
Total Operating Expense 16.848 16.137 17.009 16.578 16.045
Selling/General/Admin. Expenses, Total 9.975 9.099 9.856 9.81 10.093
Research & Development 4.164 4.23 4.483 3.932 3.583
Depreciation / Amortization 0.681 0.683 0.664 0.67 0.689
Operating Income -3.302 -2.108 -3.411 -1.974 -4.147
Interest Income (Expense), Net Non-Operating -1.68 -1.621 -1.567 -1.345 -1.256
Net Income Before Taxes -4.968 -3.781 -5.245 -3.098 -5.955
Net Income After Taxes -4.968 -3.78 -5.257 -3.115 -5.955
Net Income Before Extra. Items -4.968 -3.78 -5.257 -3.115 -5.955
Net Income -4.968 -3.78 -5.257 -3.115 -5.955
Income Available to Common Excl. Extra. Items -4.982 -3.78 -5.257 -3.115 -5.955
Income Available to Common Incl. Extra. Items -4.982 -3.78 -5.257 -3.115 -5.955
Diluted Net Income -4.982 -3.78 -5.257 -3.115 -5.955
Diluted Weighted Average Shares 7.03223 7.00032 6.99658 6.99971 6.99074
Diluted EPS Excluding Extraordinary Items -0.70845 -0.53998 -0.75137 -0.44502 -0.85184
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.70845 -0.53998 -0.75137 -0.44502 -0.85184
Unusual Expense (Income) 0 0 0
Other, Net 0.014 -0.052 -0.267 0.221 -0.552
Total Adjustments to Net Income -0.014
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 29.413 42.16 34.906 32.745 34.848
Cash and Short Term Investments 5.274 16.51 11.208 9.426 13.043
Cash & Equivalents 5.274 16.51 11.208 9.426 13.043
Total Receivables, Net 19.612 19.128 17.2 19.331 17.259
Accounts Receivable - Trade, Net 19.612 19.128 17.2 19.331 17.259
Total Inventory 1.605 2.679 2.746 1.39 2.405
Prepaid Expenses 2.892 3.809 3.718 2.565 2.109
Other Current Assets, Total 0.03 0.034 0.034 0.033 0.032
Total Assets 42.602 58.52 50.855 50.309 54.108
Property/Plant/Equipment, Total - Net 3.92 4.493 2.358 2.047 1.355
Property/Plant/Equipment, Total - Gross 7.981 7.923 6.305 5.858 4.967
Accumulated Depreciation, Total -4.061 -3.43 -3.947 -3.881 -3.612
Intangibles, Net 8.957 10.897 12.838 14.783 16.723
Other Long Term Assets, Total 0.129 0.137 0.753 0.734 1.182
Total Current Liabilities 39.732 12.592 12.348 12.048 10.234
Accounts Payable 10.088 8.706 7.461 7.077 6.355
Accrued Expenses 3.998 3.617 3.197 4.716 3.643
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 25.646 0.269 1.69 0.255 0.236
Other Current Liabilities, Total
Total Liabilities 63.41 61.125 58.833 54.754 51.386
Total Long Term Debt 18.683 43.08 42.922 38.752 38.178
Long Term Debt 18.683 43.08 42.408 38.658 37.873
Capital Lease Obligations 0.514 0.094 0.305
Other Liabilities, Total 4.995 5.453 3.563 3.954 2.974
Total Equity -20.808 -2.605 -7.978 -4.445 2.722
Preferred Stock - Non Redeemable, Net 19.227 19.227 19.227 30.344 30.344
Common Stock 0.07 0.069 0.057 0.05 0.701
Additional Paid-In Capital 378.238 377.229 365.83 350.117 346.108
Retained Earnings (Accumulated Deficit) -415.388 -397.281 -392.539 -383.863 -373.42
Other Equity, Total -2.955 -1.849 -0.553 -1.093 -1.011
Total Liabilities & Shareholders’ Equity 42.602 58.52 50.855 50.309 54.108
Total Common Shares Outstanding 6.99551 6.93515 5.71937 4.96595 4.67193
Total Preferred Shares Outstanding 0.6 0.6 0.6 0.61015 0.61015
Long Term Investments 0.183 0.833
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 35.675 29.413 29.76 33.073 34.753
Cash and Short Term Investments 13.086 5.274 5.514 7.859 9.946
Cash & Equivalents 13.086 5.274 5.514 7.859 9.946
Total Receivables, Net 18.433 19.612 19.142 20.319 18.776
Accounts Receivable - Trade, Net 18.433 19.612 19.142 20.319 18.776
Total Inventory 1.215 1.605 1.786 1.656 2.452
Prepaid Expenses 2.91 2.892 3.29 3.208 3.546
Other Current Assets, Total 0.031 0.03 0.028 0.031 0.033
Total Assets 48.239 42.602 43.429 47.574 49.931
Property/Plant/Equipment, Total - Net 3.757 3.92 3.87 3.938 4.343
Intangibles, Net 8.479 8.957 9.446 9.935 10.419
Other Long Term Assets, Total 0.131 0.129 0.118 0.126 0.134
Total Current Liabilities 14.173 39.732 34.01 25.431 17.006
Accounts Payable 9.669 10.088 8.706 7.614 6.604
Accrued Expenses 4.241 3.998 3.661 3.316 3.046
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.263 25.646 21.643 14.501 7.356
Total Liabilities 67.155 63.41 61.507 59.909 58.534
Total Long Term Debt 44.312 18.683 22.492 29.297 36.245
Long Term Debt 44.152 18.683 22.492 29.297 36.245
Capital Lease Obligations 0.16
Other Liabilities, Total 8.67 4.995 5.005 5.181 5.283
Total Equity -18.916 -20.808 -18.078 -12.335 -8.603
Preferred Stock - Non Redeemable, Net 7.728 19.227 19.227 19.227 19.227
Common Stock 0.074 0.07 0.07 0.07 0.07
Additional Paid-In Capital 378.146 378.238 378.005 377.847 377.541
Retained Earnings (Accumulated Deficit) -402.081 -415.388 -411.608 -406.351 -403.236
Other Equity, Total -2.783 -2.955 -3.772 -3.128 -2.205
Total Liabilities & Shareholders’ Equity 48.239 42.602 43.429 47.574 49.931
Total Common Shares Outstanding 7.39159 6.99551 6.99802 6.99546 6.99265
Total Preferred Shares Outstanding 0.012 0.6 0.6 0.6 0.6
Long Term Investments 0.197 0.183 0.235 0.502 0.282
Other Current Liabilities, Total
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -18.107 -4.372 -5.339 -10.443 -16.382
Cash From Operating Activities -9.975 -3.224 -2.193 -4.152 -11.553
Cash From Operating Activities 2.706 2.579 2.676 2.641 2.645
Deferred Taxes 0.116 0.61 0.031 0.454 -0.653
Non-Cash Items 2.621 -0.692 1.829 3.377 7.084
Cash Taxes Paid 0.232 0.112 0.11 0.239 0.239
Cash Interest Paid 4.489 4.302 4.556 4.419 3.571
Changes in Working Capital 2.689 -1.349 -1.39 -0.181 -4.247
Cash From Investing Activities -0.255 -0.621 -0.62 -0.174 -0.175
Capital Expenditures -0.255 -0.621 -0.62 -0.174 -0.175
Cash From Financing Activities -0.302 9.823 3.882 0.869 0.95
Financing Cash Flow Items -0.113 0 -0.019 -2.227 -3.808
Issuance (Retirement) of Stock, Net 0.1 10.044 0.049 0.902 0.085
Issuance (Retirement) of Debt, Net -0.289 -0.221 3.852 2.194 4.673
Foreign Exchange Effects -0.708 -0.676 0.714 -0.159 -0.248
Net Change in Cash -11.24 5.302 1.783 -3.616 -11.026
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -4.968 -18.107 -14.327 -9.07 -5.955
Cash From Operating Activities -2.209 -9.975 -9.724 -7.811 -6.213
Cash From Operating Activities 0.681 2.706 2.023 1.359 0.689
Non-Cash Items 0.507 2.621 2.095 1.318 1.027
Cash Taxes Paid 0 0.232 0.224 0.182 0.018
Cash Interest Paid 1.354 4.489 3.253 2.145 1.061
Changes in Working Capital 1.571 2.689 0.485 -1.418 -1.974
Cash From Investing Activities -0.009 -0.255 -0.171 -0.041 -0.149
Capital Expenditures -0.009 -0.255 -0.171 -0.041 -0.149
Cash From Financing Activities 9.998 -0.302 -0.109 -0.164 -0.062
Financing Cash Flow Items -3.123 -0.113
Issuance (Retirement) of Debt, Net 2.373 -0.289 -0.164 -0.204 -0.062
Foreign Exchange Effects 0.033 -0.708 -0.998 -0.638 -0.141
Net Change in Cash 7.813 -11.24 -11.002 -8.654 -6.565
Issuance (Retirement) of Stock, Net 10.748 0.1 0.055 0.04
Deferred Taxes 0.116
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Velan Capital Investment Management LP Investment Advisor/Hedge Fund 22.4131 1659654 1401901 2023-05-17 MED
Ocumension Therapeutics Corporation 15.4621 1144945 0 2023-04-24 LOW
Morgan Stanley & Co. LLC Research Firm 8.9243 660832 0 2023-03-31 MED
Caligan Partners, LP Hedge Fund 6.4657 478777 0 2023-05-17 MED
Eiswirth (Richard S Jr) Individual Investor 4.3555 322518 500 2023-04-24 LOW
HOOPP Investment Management Pension Fund 3.3762 250000 0 2023-03-31 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.0071 148624 0 2023-03-31 LOW
Ashman Philip Individual Investor 1.8004 133315 0 2023-04-24 MED
Holland (David R) Individual Investor 1.4704 108880 500 2023-04-24 LOW
Renaissance Technologies LLC Hedge Fund 1.3693 101394 -1100 2023-03-31 HIGH
Skibsted (Russell L) Individual Investor 1.0196 75500 58000 2023-03-26 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5167 38262 0 2023-03-31 LOW
Jones (John Philip) Individual Investor 0.4347 32186 372 2022-10-31
Millennium Management LLC Hedge Fund 0.3884 28762 16799 2023-03-31 HIGH
Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.2639 19542 0 2023-03-31 MED
Bridgeway Capital Management, LLC Investment Advisor 0.2471 18300 0 2023-03-31
Perritt Capital Management, Inc. Investment Advisor 0.2431 18000 0 2023-03-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.175 12962 438 2023-03-31 LOW
J.P. Morgan Securities LLC Research Firm 0.14 10364 9838 2023-03-31 MED
Snisarenko (John) Individual Investor 0.135 10000 0 2023-04-24 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

535K+

Traders

87K+

Active clients monthly

$113M+

Monthly investing volume

$64M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Alimera Sciences, Inc. Company profile

About Alimera Sciences Inc

Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Alimera Sciences Inc revenues increased 16% to $59M. Net loss decreased 18% to $4.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects DEPRECIATION AND AMORTIZATION decrease of 4% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.04 to -$0.66.

Equity composition

Common Stock $.01 Par, 05/11, 100M auth., 31,348,197 issd. IPO:TBA. Insider owns 2.06%.

Industry: Biopharmaceuticals

Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US

Income Statement

  • Annual
  • Quarterly

People also watch

US100

14,553.50 Price
+0.340% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 3.0

BTC/USD

25,697.55 Price
-2.960% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

Oil - Crude

70.46 Price
-0.840% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee -0.0026%
Overnight fee time 21:00 (UTC)
Spread 0.03

XRP/USD

0.49 Price
-9.180% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00316

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading